Form 4 Filing for Aprea Therapeutics, Inc.

Michael Grissinger, a director at Aprea Therapeutics, Inc., reported a series of transactions on June 16, 2026. He acquired 3,135 shares of Common Stock and was granted 12,555 stock options. The Common Stock acquisition, valued at $0.00, brings his post-transaction holdings to 6,024 shares. The stock options, also acquired at no cost, vest on June 16, 2027, and have an exercise price of $0.7293 per share, with 12,555 underlying shares of Common Stock. These transactions were reported on a Form 4 filing.